Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Latin America Cutaneous Oncology Management (LACOM) II: A Practical Algorithm for Managing Skin Toxicities in Oncology Patients.

Journal of drugs in dermatology : JDD·2026
Same author

Sparse Insurance and Alopecia Information Availability Among New York City Wig Providers: A Cross-Sectional Study.

Journal of the American Academy of Dermatology·2026
Same author

Secondary T-cell lymphomas after chimeric antigen receptor T-cell therapy in dermatology.

Journal of the American Academy of Dermatology·2026
Same author

Efficacy of intravenous immunoglobulin in children with drug-resistant epilepsy.

Frontiers in neurology·2026
Same author

High Curl Pattern Hair and Scalp Care Considerations to Mitigate Seborrheic Dermatitis.

Journal of cosmetic dermatology·2026
Same author

Classification of High Curl Pattern Hair: A Systematic Review and Clinical Perspective.

Journal of cosmetic dermatology·2026

Related Experiment Video

Updated: Jul 8, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.9K

INDIVIDUAL ARTICLE: USCOM IV Algorithm for the Prevention and Management of Targeted Therapy-Related Cutaneous

Jonathan Leventhal, Ana Sofia Acosta Madiedo, Anneke Andriessen

    Journal of Drugs in Dermatology : JDD
    |December 4, 2024
    PubMed
    Summary

    Targeted cancer therapies can cause skin issues. The US Cutaneous Oncodermatology Management (USCOM) algorithm offers practical guidance for preventing and managing these adverse events to improve patient quality of life.

    More Related Videos

    Diffuse Optical Spectroscopy for the Quantitative Assessment of Acute Ionizing Radiation Induced Skin Toxicity Using a Mouse Model
    06:21

    Diffuse Optical Spectroscopy for the Quantitative Assessment of Acute Ionizing Radiation Induced Skin Toxicity Using a Mouse Model

    Published on: May 27, 2016

    8.1K
    A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
    07:22

    A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

    Published on: March 14, 2025

    235

    Related Experiment Videos

    Last Updated: Jul 8, 2026

    The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
    11:39

    The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

    Published on: July 11, 2013

    38.9K
    Diffuse Optical Spectroscopy for the Quantitative Assessment of Acute Ionizing Radiation Induced Skin Toxicity Using a Mouse Model
    06:21

    Diffuse Optical Spectroscopy for the Quantitative Assessment of Acute Ionizing Radiation Induced Skin Toxicity Using a Mouse Model

    Published on: May 27, 2016

    8.1K
    A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
    07:22

    A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

    Published on: March 14, 2025

    235

    Area of Science:

    • Oncodermatology
    • Cancer Therapeutics
    • Adverse Event Management

    Background:

    • Targeted therapies have enhanced cancer treatment outcomes.
    • Dermatologic adverse events are common side effects impacting patient quality of life.
    • Effective management strategies are crucial for maintaining treatment adherence and well-being.

    Purpose of the Study:

    • To introduce the US Cutaneous Oncodermatology Management (USCOM) algorithm.
    • To provide practical, multidisciplinary recommendations for preventing and managing skin toxicities.
    • To support cancer patients and survivors experiencing targeted therapy-related dermatologic adverse events.

    Main Methods:

    • An advisory board identified six common cutaneous adverse events.
    • Recommendations were developed through literature review, clinical expertise, and expert opinion.
    • A multidisciplinary approach guided the algorithm's creation.

    Main Results:

    • Six key adverse events were identified: acneiform rash, pruritus, xerosis, paronychia, hyperpigmentation, and hand-foot skin reaction.
    • Practical prevention and treatment strategies for each condition are outlined.
    • The algorithm provides actionable steps for healthcare providers.

    Conclusions:

    • The USCOM algorithm is designed for healthcare providers managing oncology patients on targeted therapies.
    • Prompt diagnosis and multidisciplinary care, including dermatologists and oncologists, are essential.
    • Effective management optimizes quality of life and cancer treatment outcomes.